ESMO Open
@ESMO_Open
Followers
6K
Following
95
Statuses
3K
The Open Access journal of @myESMO dedicated to oncology research
Joined September 2015
RT @PTarantinoMD: Breast cancers with ERBB2 het loss appear resistant to T-DXd. But what’s distinct about these tumors? By leveraging mult…
0
32
0
RT @DrJNaidoo: BEAT-MESO trial of 1L carbo/pem/bev +/- atezolizumab in pleural mesothelioma @ESMO_Open: - 400pts - did not meet it’s prima…
0
13
0
RT @ElisaAgostinett: Out in @ESMO_Open by @hoperugo and colleagues, real-world data on CDK4/6i in #breastcancer 🌎 No significant OS differ…
0
19
0
RT @StephenVLiu: Results from phase III ETOP 13 18 BEAT-meso trial @ESMO_Open. Adding atezolizumab to carboplatin + pemetrexed + bevacizuma…
0
14
0
RT @drenriquegrande: ⚡️ On @ESMO_Open - Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and a…
0
6
0
RT @DFCI_BreastOnc: Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway…
0
19
0
RT @dr_yakupergun: Comparative OS of CDK4/6is plus an AI in HR+/HER2− mBC n the US real-world setting 9146 pts 💥There were no significant…
0
36
0
RT @bpellegrino89: 🚀 Excited to share our last publication from the @gruppomito: "Unraveling the complexity of HRD in OvC by combining geno…
0
1
0
RT @oncodaily: One of the most important aspects of care is end of life care - @oncology_bg
@ChernyNathan @ESMO_Open
0
1
0
RT @UHN_Supportive: #NewPublication from @ZimmTeamLab and colleagues in @ESMO_Open: "A taxonomy of the factors contributing to the overtrea…
0
1
0
RT @tuttsakhil: Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTI…
0
3
0
Hot off the press - an IGG gene signature links to longevity in breast cancer survivors, reduced death risk across cancers, and it correlates with TLS and B-/T-cell polyclonality.
2
15
20
RT @OncologyAdvance: See this month’s highlights from the @myESMO portfolio. Featured content from @Annals_Oncology, @ESMO_Open, @ESMO_IOTE…
0
1
0
RT @dr_yakupergun: Practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2− advanced breast cancer 💥Ex…
0
19
0
RT @santhoshak23220: Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developi…
0
1
0
RT @fedgiugliano: Published in @ESMO_Open our latest article, describing characteristics and treatment patterns of patients with high risk…
0
12
0
RT @Erman_Akkus: 💉>70 y metastatic CRC pts, second line treatment ❓FOLFIRI-aflibercept until progression vs. 5FU-aflibercept maintenance a…
0
21
0
RT @FrancescoSche20: Finally out in @ESMO_Open the main findings of my @myESMO #Fellowship research project focused on the identification o…
0
22
0
RT @ElisaAgostinett: Now out in @ESMO_Open results of the NEOENDO translational study by @FrancescoSche20 & @prat_aleix team 🇪🇸 identifying…
0
7
0
RT @santhoshak23220: Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry - ESMO Open @ESMO…
0
1
0